Shire attacks treatment monopoly of Sanofi
Enlarge image


Shire attacks treatment monopoly of Sanofi

29.06.2012 - For over a decade, Sanofi’s Cerezyme has dominated the market of therapies for Gaucher disease. Now, Shire challenges the drug with new results.

Dublin/Paris/ Carmiel/ Cambridge – Results from a head-to-head Phase III clinical study with Sanofi’s Gaucher disease therapy imiglucerase (Cerezyme) suggest that Shire’s enzyme replacement therapy velaglucerase alfa (VPRIV) offers a unique benefit to patients. According to the Irish drugmaker, only patients treated with VPRIV experienced statistically significant improvement in lumbar spine bone mineral density after nine months of treatment. This, together with a 15% lower price than Aventis‘ expensive type 1 Gaucher treatment could give the Irish an advantage in the market for the rare disease, that is narrow but lucrative.

Until VPRIV was approved in 40 countries, Aventis subsidiary Genzyme was able to charge $200,000 per year per patient for its treatment that dates back to 1997, but other players are now trying to get a piece of the cake. Pfizer and its development partner Protalix currently got US market authorisation for its plant-cell based enzyme expression therapy Elelyso (taliglucerase alfa) but it was rebuffed at the end of June by the EMA. VPRIV is made in a human cell line using Shire’s gene activation technology.

Type 1 Gaucher disease is caused by a lack of the enzyme β-glucocerebrosidase, which normally breaks down a fatty waste product called glucosylceramide. Without the enzyme, glucosylceramide builds up in the body, typically in the liver, spleen and bone marrow, which produces the symptoms of the disease: anaemia (low red blood cell counts), tiredness, easy bruising and a tendency to bleed, an enlarged spleen and liver, and bone pain and breaks. The latter symptoms are now addressed by Shires enzyme replacement therapy, according to surrogate marker data presented at the European Working Group on Gaucher Disease (EWGGD) meeting in Paris.


07.10.2015 T-cell specialist Adaptimmune Therapeutics plc needs more space for its R&D in immuno-oncology. The expanding UK company is building a major facility that will house 200 staff.

Drug DiscoveryGermany

06.10.2015 Evotec has been hired by the US National Cancer Institute (NCI) to provide compound management services to the Chemical Biology Consortium. The goal: the discovery of new cancer treatments.

Drug DevelopmentUKBelgium

01.10.2015 Autoimmune disease specialist Apitope has raised €12m in a Series B financing round and is relocating its UK headquarters to Wales.

Drug DevelopmentFranceEUFinlandSpainItalyAustria

01.10.2015 Paris-based BEAM Alliance, a network of companies working on novel antibiotics founded earlier this year, has released its first position paper.


29.09.2015 Swiss CNS specialist Asceneuron SA has raised CHF30m (€27.5m) in a Series A financing, winning Paris-based Sofinnova Partners as its largest investor.


28.09.2015 US company Aduro Biotech has acquired Dutch monoclonal antibody discovery and development firm BioNovion for €29m plus milestones.


24.09.2015 Nutrition company Nestlé is teaming up with biopharmaceutical company AC Immune SA to develop a Tau diagnostic assay for early Alzheimer’s.


22.09.2015 Bayer has taken another step in its restructuring and development as a life sciences company after splitting from all its chemical divisions.


18.09.2015 AstraZeneca has partnered up with the US Department of Health in order to accelerate the development of new antibiotics. The goal: to be prepared for multi-resistant bugs – and for bioterrorism.


17.09.2015 Another European biotech is coming with a hefty price tag for its US buyer. Amgen Inc. has acquired privatly held Dutch company Dezima Pharma B.V. for US$1.55bn (€1.37bn).


All Events

Current issue

All issues

Product of the week


Stock list

All quotes


  • MOLMED (I)0.37 EUR8.82%


  • THERAMETRICS (CH)0.05 CHF-16.67%
  • MDX HEALTH (B)3.50 EUR-14.84%


  • CHRONTECH PHARMA (S)0.36 SEK3500.0%
  • THROMBOGENICS (B)4.16 EUR48.0%
  • OREXO (S)66.75 SEK36.5%


  • TRANSGENE (F)2.78 EUR-43.6%
  • NEOVACS (F)0.69 EUR-24.2%


  • KARO BIO (S)44.20 SEK5161.9%
  • CHRONTECH PHARMA (S)0.36 SEK414.3%
  • GALAPAGOS (B)41.63 EUR258.0%


  • NEOVACS (F)0.69 EUR-78.6%
  • BIOTEST (D)19.45 EUR-74.5%
  • EVOCUTIS (UK)0.16 GBP-71.9%

No liability assumed, Date: 06.10.2015